It’s been less than a year since Genzyme started offering the first-ever pill to treat the very rare disease known as Gaucher. Now it’s one of two big drug companies in the world aiming to do the same thing with a related rare disease, called Fabry.
The Cambridge company now offers Cerdelga, its oral drug for Gaucher launched last August, and the intravenously-administered enzyme replacement therapy called Cerezym, which was Genzyme’s second approved drug when it launched 25 years ago. Today both drugs are comparably priced, allowing patients to choose between a daily pill or infusions every two weeks.
Help employers find you! Check out all the jobs and post your resume.
The Cambridge company now offers Cerdelga, its oral drug for Gaucher launched last August, and the intravenously-administered enzyme replacement therapy called Cerezym, which was Genzyme’s second approved drug when it launched 25 years ago. Today both drugs are comparably priced, allowing patients to choose between a daily pill or infusions every two weeks.
Help employers find you! Check out all the jobs and post your resume.
